Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report

Table 3

Summary of adverse events.

Toxicity	DAC		DAC + chemo		DAC + CIK
	Grades 1-2; 𝑛 (%)	Grades 3-4; 𝑛 (%)	Grades 1-2; 𝑛 (%)	Grade 3-4; 𝑛 (%)	Grades 1-2; 𝑛 (%)	Grades 3-4; 𝑛 (%)
Neutrogena	1 (12.5)	1 (12.5)	10 (55.56)	6 (33.33)	2 (40)	1 (20)
Nausea	0 (0)	0 (0)	5 (27.78)	0 (0)	0 (0)	0 (0)
Fatigue	0 (0)	2 (25)	5 (27.78)	0 (0)	2 (40)	0 (0)
Drowsiness	0 (0)	1 (12.5)	2 (11.11)	0 (0)	0 (0)	0 (0)
Thrombocytopenia	0 (0)	0 (0)	1 (5.56)	0 (0)	0 (0)	0 (0)
Hyperhidrosis	0 (0)	0 (0)	1 (5.56)	0 (0)	0 (0)	0 (0)

Note. Data is 𝑛 (%). CIK: cytokine induced killer cells; DAC + chemo: decitabine in combination with chemotherapy; DAC + CIK: decitabine in combination with CIK.